EUCTR2015-001834-15-DE进行中（未招募）1 期
An open label, single group, long term safety extension trial of BI 655066/ABBV-066 (risankizumab), in patients with moderately to severely active Crohn's disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Patients with Crohn's disease, who have successfully completed the preceding trial 1311.6. Successful treatment is defined as:
- •a. Completion of period 2 in 1311.6 with a clinical response (drop in
- •Crohn's Disease Activity Index from baseline by >=100) but no remission (Crohn's Disease Activity Index <150) at Visit E1; or
- •b. Completion of period 3 in 1311.6 with a clinical response (drop in
- •Crohn's Disease Activity Index from baseline by >=100) or remission
- •(Crohn's Disease Activity Index < 150) at Visit E5;
- •- Female patients:
- •a. Women of childbearing potential (not surgically sterilized and
- •between menarche and 1 year postmenopause), who, if sexually active, agree to use one of the appropriate medically accepted methods of birth control in addition to the consistent and correct use of a condom from date of screening until 20 weeks after last administration of study medication. Medically accepted methods of contraception are: ethinyl estradiol containing contraceptives, diaphragm with spermicide substance, and intra-uterine-device, or
- •b. Surgically sterilized female patients with documentation of prior
- •hysterectomy, tubal ligation or complete bilateral oophorectomy, or
- •c. Postmenopausal women with postmenopausal is defined as permanent cessation >=1 year of previously occurring menses, and
- •d. Negative urine pregnancy test at screening. Serum ß-Human Chorionic Gonadotrophin (ß-HCG) pregnancy test will be done at
- •screening only in case when urine pregnancy test is positive.
- •- Male patients:
- •a. Who are documented to be sterile, or
- •b. Who consistently and correctly use effective method of contraception (i.e. condoms) during the study and 20 weeks after last administration of study medication.
- •- Be able to adhere to the study visit schedule and other protocol
- •requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 55
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •- Patients who were not compliant with key study procedures (colonoscopy, treatment compliance, endpoint assessment, contraception measures) in preceding trial 1311.6
- •- Patients who could not tolerate BI 655066/ABBV-066 (risankizumab) treatment for tolerability or safety reasons in the preceding trial
- •- Are pregnant, nursing, or planning pregnancy while enrolled in the study, or within 20 weeks after receiving the last dose of study medication.
- •- Patients must agree not to receive a live virus or bacterial or Bacille Calmette-Guérin vaccination during the study or up to 12 months after the last administration of study drug.
- •- Patients who have developed malignancy, or suspicion of active malignant disease during the preceding trial
- •- Are intending to participate in any other study using an investigational agent or procedure during participation in this study.
- •- Cannot adhere to the concomitant medication requirements
研究者
相似试验
进行中（未招募）
1 期
A long term extension trial of BI 655066 in patients with moderately to severely active Crohn's diseaseCrohn's diseaseEUCTR2015-001834-15-NLAbbVie Deutschland GmbH & Co. KG65
进行中（未招募）
1 期
A long term extension trial of BI 655066 in patients with moderately to severely active Crohn's diseaseMedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000016693Crohn's diseaseEUCTR2015-001834-15-BEAbbVie Deutschland GmbH & Co. KG62
进行中（未招募）
1 期
A long term extension trial of BI 655066 in patients with moderately to severely active Crohn's diseaseMedDRA version: 18.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856Crohn's diseaseEUCTR2015-001834-15-ESBoehringer Ingelheim España, S.A.62
已完成
2 期
An Open Label, Single Group, Long Term Safety Extension Trial of BI655066/ABBV-066 (Risankizumab), in Patients with Moderately to Severely Active Crohn's Disease.Crohn's disease - inflammatory bowel disease10017969NL-OMON47395AbbVie6
进行中（未招募）
1 期
An open-label, long-term, safety and tolerability study of SAR445088 in participants with cold agglutinin disease previously treated with SAR445088 or never treated with SAR445088Autoimmune haemolytic anaemiaMedDRA version: 20.0Level: PTClassification code: 10073785Term: Autoimmune haemolytic anaemia Class: 100000004851CTIS2023-510210-68-00Bioverativ USA Inc.18